PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2019.08620195141549-1556Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean PatientsYeonjoo Choi, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Dalyong Kim, Jong Gwon Choi, Ja Young Seo, Inkeun Park, Jae Lyun Leehttp://e-crt.org/upload/pdf/crt-2019-086.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2019.086, http://e-crt.org/upload/pdf/crt-2019-086.pdf
BMC Urology10.1186/s12894-019-0484-22019191Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failuresInkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Leehttp://link.springer.com/content/pdf/10.1186/s12894-019-0484-2.pdf, http://link.springer.com/article/10.1186/s12894-019-0484-2/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12894-019-0484-2.pdf
Uropathology10.1007/978-3-030-41894-6_48252020143-145Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell CarcinomaAnna Caliò, Diego Segala, Guido Martignonihttp://link.springer.com/content/pdf/10.1007/978-3-030-41894-6_4825
Pathology10.1016/j.pathol.2021.12.143202254S44-S45Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: A case reportAsher Goh, Benjamin Popphttps://api.elsevier.com/content/article/PII:S0031302521006863?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0031302521006863?httpAccept=text/plain
Uropathology10.1016/b978-0-323-65395-4.00158-52023338-339Fumarate hydratase-deficient renal cell carcinoma, including hereditary leiomyomatosis and renal cell carcinoma syndromeMing Zhouhttps://api.elsevier.com/content/article/PII:B9780323653954001585?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323653954001585?httpAccept=text/plain
Encyclopedia of Pathology10.1007/978-3-319-28845-1_4825-120191-3Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell CarcinomaAnna Caliò, Diego Segala, Guido Martignonihttp://link.springer.com/content/pdf/10.1007/978-3-319-28845-1_4825-1
Diagnostic Pathology: Genitourinary10.1016/b978-0-323-37714-0.50012-2201620-23Hereditary Leiomyomatosis Renal Cell Carcinoma Syndromehttps://api.elsevier.com/content/article/PII:B9780323377140500122?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323377140500122?httpAccept=text/plain
Cancer10.1002/cncr.254972010116143309-3309Study comparing bevacizumab plus temsirolimus versus bevacizumab plus interferon-α in advanced renal cell carcinoma subjects (INTORACT)Carrie Printzhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25497, http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25497/fullpdf
European Journal of Cancer10.1016/s0959-8049(14)70131-520145085 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinibR. Srinivasan, D. Su, L. Stamatakis, M.M. Siddiqui, E. Singer, B. Shuch, J. Nix, J. Friend, G. Hawks, J. Shih, P. Choyke, W.M. Linehanhttps://api.elsevier.com/content/article/PII:S0959804914701315?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804914701315?httpAccept=text/plain
OncoTargets and Therapy10.2147/ott.s81572010179The bevacizumab experience in advanced renal cell carcinomaLauren Harshmanhttps://www.dovepress.com/getfile.php?fileID=7677